Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at a uniquely high risk of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. The pre-emptive treatment model whereby asymptomatic post-transplant patients are routinely screened with treatment initiated if found viremic has recently been shown to be superior in terms of patient mortality when compared to deferring laboratory assessment and treatment until symptoms emerge. This study analyzes the cost-effectiveness of the pre-emptive therapy model in patient care dollars per quality-adjusted life years (QALY). PATIENTS AND METHODS: Utilization and outcome data were compiled as a retrospective cohort study of 96 pediatric patients receiving HSCT at University of California Los Angeles Pediatric Hematology/Oncology Department between the years 2006 and 2010. Two-decision tree models were constructed for each the preemptive model and the deferred model wherein costs and probability assumptions were based on either previously published literature or calculated from this study cohort.
T he reality of opportunistic viral infections in immunocompromised transplant populations has been a point of robust research and discussion in recent years. In the hematopoietic stem cell transplant (HSCT) patient population two commonly afflicting viruses are Epstein-Barr virus (EBV) and cytomegalovirus (CMV), both of the gamma herpesvirus family. These viruses are known to establish latent infections in their host after an initial acute disease and both are ubiquitous in both healthy and ill populations with positive serologies in up to 90% and 81% of the adults for EBV and CMV respectively. 1, 2 These viruses uncommonly result in serious disease in the immunocompetent host, as specific clonally expanded antiviral CD8+ cytotoxic Tlymphocytes control viral replication by targeting the B-lymphocytes and monocytes that harbor the latent viral particles and are thus adorned with viral nuclear antigens. 3 However, it is well documented that the iatrogenic immunosuppression implicated in HSCT gives rise to conditions amenable to viral reactivation and replication, leading to a viremic state occasionally followed by clinical disease. [4] [5] [6] It is believed that this is facilitated by the relative T-cell depletion in proportion to latent-viral containing B-cells which is created in vivo by way of antihuman thymocyte globulin (ATG) administration or ex vivo by way of T-cell depleted graft marrow, both common strategies to counteract potential graft-vs-host disease. 7, 8 Specifically concerning CMV, multiple studies that show the highest incidence of CMV viremia (60-80%) and disease are in those patients who were CMV seronegative but received a graft from a CMV seropositive donor (D+/RÀ), with a median time to seroconversion between the 2nd and 5th week after transplant. 9 CMV disease can manifest in a patient in multiple ways: fever, pneumonitis, pancreatitis, colitis, chorioretinitis, meningoencephalitis, marrow suppression, or elevation in liver enzymes. 9, 10 On the other hand, the most concerning disease implicated in EBV reactivation is post-transplant lymphoproliferative disorders (PTLD). PTLD is a heterogeneous group of disorders which can include benign polyclonal hyperplasia but most commonly this PTLD takes the form of monomorphic NonHodgkin's Lymphoma, particularly diffuse large B-cell type.
11 Presentation might include fever or a sepsis syndrome, but can quickly transform into a lymphoma presentation involving nearly any organ. PTLD has a 1% incidence in bone marrow transplant recipients in the first 10 years post-transplant with highest incidence one to five months after transplant and the majority developing within the first year. 4 Pediatric patients are at particular risk of PTLD as they are more likely to be seronegative at time of transplant, and thus this incidence risk increases to 25% in pediatric patients receiving HLA-matched unrelated donors or mismatched family members. 12, 13 Recent advances in polymerase chain reaction (PCR) clinical laboratory assays have allowed for detection, amplification, and quantification of viral nucleic acids. This has allowed for routine monitoring of HSCT patients for a viremia that might portend the development of viral disease, thus allowing for pre-emptive therapy which recent evidence has shown to be more effective at prevention of morbidity and mortality than a deferred therapy model in which treatment is instigated by evidence of clinical disease. 8 In conformance with these studies, clinicians in University of California Los Angeles (UCLA) Pediatric Hematology/Oncology Department utilize routine EBV and CMV PCR screening of their pediatric HSCT population, initiating therapy upon evidence of viremia. However, these viral assays and the resultant treatments are not without significant cost, both in terms of healthcare dollars as well as therapy-related toxicity in a patient whose viremia might otherwise resolve without treatment or clinical disease. Accordingly, this study contains a cost-effectiveness analysis to assess the efficacy in terms of an incremental cost-effectiveness ratio (ICER) and quality-adjusted life years (QALYs) of pre-emptive viral therapy requiring routine screening as utilized at UCLA versus deferred viral assays and therapy.
MATERIALS AND METHODS

Study population
This is a retrospective cohort study assembling the costs and outcomes of pediatric HSCT patients transplanted between 2006 and 2010 by the UCLA Pediatric Hematology Oncology service. Institutional Review Board approval was secured for outcome studies involving this patient population. Of the 108 patients transplanted during this time period, 12 were excluded from the study due to insufficient records accessible during the period of UCLA's transition to electronic medical records in 2005. Thus, the study population constituted 96 patients below the age of 21 at the time of transplant who received their graft and subsequent post-transplant care at UCLA's Center for Health Sciences or Ronald Reagan Hospital and associated outpatient clinics. The patient characteristics and indications for transplant are outlined in Table 1 . During their time as inpatients after transplant, patients undergo biweekly quantitative PCR assays for CMV and EBV viral copy numbers. After discharge, there are routine clinic visits once every two weeks for the first 100 days after transplant, then once a month up until 1 year after transplant, then once every three months until 5 years after transplant, followed by once yearly thereafter. Patients continue receiving EBV and CMV PCR evaluations at each clinic visit until 1 year after transplant. In adhering to this routine of EBV and CMV quantitative screening and initiating therapeutic interventions for evidence of viremia, clinicians at UCLA are implementing a preemptive treatment algorithm and therefore their PCR assay utilization patterns and associated costs are a subject of analysis in this study.
Assay utilization and cost
For the purpose of this study, each patient's transplant course was divided into three segments to categorize the timing of virology testing: pre-transplant was the point of initial assessment until transplant; peri-transplant was the period from the date of transplant to 100 days after transplant; and post-transplant was 100 days after transplant until January 2012 when this study was performed. The peri-transplant period was bounded by 100 days after transplant as this is the clinically significant time frame after which a patient's immune system is most commonly fully reconstituted.
14 The replicative virology tests drawn on our patient population were Quantitative CMV PCR, Qualitative PCRs, CMV DNA Quantitation, CMV Early-Antigen, Quantitative EBV PCR, and EBV DNA Quantitation. The serology tests of interest were CMV IgG, CMV IgM, EBV Early-Antigen IgG, EBV VCA IgG, EBV VCA IgA, EBV VCA IgM, and EBV EBNA IgG.
Assay cost data was based on Center for Medicare and Medicaid Services reimbursements to UCLA Hospital Systems as publicly available and confirmed by representatives from our central clinical laboratory. 15 All prices are expressed in 2010 USD (Table 2) .
Cost-efficiency analysis A decision tree model was created comparing the potential outcome space of hypothetical patients undergoing transplant following one of two algorithms: preemptive virology therapy vs. deferred virology therapy ( Figure 2 ). Given that UCLA's Pediatric Hematology/Oncology department has utilized routine screening and pre-emptive therapy for many years, their historical cost and utilization data was incorporated to represent the pre-emptive model while the deferred model was an extrapolation from existing cost data but under different utilization assumptions. For the pre-transplant period, screening costs in the deferred model were assumed to match those in the UCLA pre-emptive experience, as serologic workup would likewise be required. In addition, screening costs were built into the deferred model during patient disease states, capturing the resultant increased surveillance. The increase in surveillance assumptions were derived from the assay utilization patterns observed in our study, and outlined in the Results section to follow. In both models, all utility assumptions of various disease states and the probability of a given disease state were derived from previously published literature or data presented in this study. 5, [16] [17] [18] [19] [20] The utility of states in which the child is asymptomatic and can be discharged home on oral medications (as with asymptomatic CMV viremia requiring oral valganciclovir) was assumed to be 1, except in states of toxicity. In the absence of toxicity or recurrent disease, life expectancy was assumed to be 78.5 years. 21 Screening costs were forecast given an assumed age of transplant original research report of 9 years old as this was the average age in our sample at transplant. Cost assumptions for anti-viral therapy were incorporated in both models given that probability differences of required treatments would impact overall cost of the paradigm. Extracted from existing literature, costs were incorporated for treating CMV disease in event of patient recovery or death, for treating false positive elevations in CMV viral copy numbers, and for treating the potential non-Hodgkin's lymphoma arising from PTLD. 16, 20 These cost assumptions are outlined in Figure 2 .
The primary output of interest in this cost-efficiency analysis was the $USD per QALY difference between the pre-emptive model and the deferred model: the incremental cost-effectiveness ratio (ICER).
The analytic horizon of this analysis extended to outcomes attributable to the progression of EBV/ CMV viremia or disease only. Given that this analysis focuses solely on the incremental cost-effectiveness ratio of routine virology screening vs. deferred therapy, all cost and utility components shared between the two protocols were not modeled. For example, no attempt was made to incorporate QALY implications of non-engraftment or primary disease progression, as the risk of these costs do not differ markedly between the two models and thus would not have an impact on the difference between the two models: the ICER.
A sensitivity analysis was performed by varying utility and probability assumptions across the range of values supported by published literature: the rate of PTLD in the deferred group varied between 1% and 17%, the rate of EBV viremia seen varied between 1% and 48%, the CMV progressing to death varied up to 40%, and cost of virology assays increased by 50%.
4,22
Outcomes CMV viremia was defined as a CMV Qualitative/ Quantitative/Quantitation PCR being elevated above zero in two consecutive assays in the peri-transplant or post-transplant period. CMV disease was defined as evidence of CMV viremia in conjunction with evidence of an organ specific infection without another source (pneumonitis, pancreatitis, colitis, chorioretinitis, meningoencephalitis, marrow suppression, or elevation in liver enzymes). In adherence with the preemptive therapy protocol, in all patients in our sample, evidence of asymptomatic CMV viremia was treated with three months of oral valganciclovir. The cost assumptions for three months of valganciclovir in 2010 USD was $9,277. 16 Evidence of CMV disease was treated with roughly one month of intravenous ganciclovir followed by several months of oral valganciclovir. This cost was estimated to be $30,519. 16 EBV Quantitative PCR threshold for considering a positive test was 1000 copies/uL. When there was evidence of EBV viremia, the treatment team responded by lowering immunosuppression -most commonly a reduction in prednisone or cyclosporine -and increasing viremia surveillance. In all cases, this led to full resolution of viremia without development of EBV-related disease.
RESULTS
Assay utilization
An average of 28 virology assays were performed per patient at UCLA as a part of their pre-transplant evaluation and peri-transplant workup for the first 100 days ( Table 3 ). The majority was serologic studies in the pre-transplant period (five per patient) and viral replicative assays in the peri-transplant period (20 per patient). In terms of assay cost per patient, this equates to an average of $1,501 per patient through the first 100 days after transplant. After this, in the post-transplant period, there were on average three virology tests performed on these patients every month, the majority of these being virus replication assays. This came to an average cost of $176 per patient per month in the post-transplant period (Table 3). For patients who were CMV PCR(À), 27 CMV PCR assays were performed per patient, while 32 patients who were CMV PCR(+) (27 of whom never developed clinical disease) 41 CMV PCR assays per patient were performed, an increase of 50%. Similarly, the presence of EBV viremia increased the EBV PCRs performed on a patient three-fold, from 17 for EBV PCR(À) patients, to 55 for those who at one time were documented as viremic.
Patient outcomes
The average length of patient clinical following in this study was 24 months (Figure 1) . The five-year overall survival in the study population was 71%. Of the 96 patients in this study, four (4.2%) were found on EBV PCR to have EBV viremia on >1000 copies/ uL. However, no patients in our study went on to develop PTLD during this study period. Additionally, 32 patients (33%) were found to have CMV viremia, while five went on to have symptomatic CMV disease subsequent to transplant (Table 1) . This incidence matches published data in adult HSCT patients.
Two of the patients in the study were diagnosed with CMV colitis; two were diagnosed with hemorrhagic cystitis; and one was diagnosed with CMV pneumonia.
Cost-effectiveness analysis
Our analysis indicates that pre-emptive screening and therapy will result -as illustrated by the UCLA experience -in an average of 28 serologic and PCR assays through the peri-transplant period. This will be followed by an average of three assays per month in the immediate post-transplant period, at a cost of $176 per month which tapers off as the post-transplant period lengthens. When assuming an age at transplant of nine (the average age in our sample) and the pre-emptive model probabilities and unweighted cost assumptions outlined in Figure 2 , the pre-emptive therapy model sums to an average probability-weighted cost per patient of $9,699 until the patient turns 21 years old. Alternatively, the deferred therapy model achieves a lower cost through the pretransplant period of $278 per patient; however, the cost of this model subsequently rises when adhering to the probabilities of high-cost disease states outlined in Figure 2 : the projected total cost per patient of the deferred model is $19,284. Using the aforementioned utility and probability assumption, the pre-emptive model illustrated probability-weighted utility benefit of 0.958 versus 0.927 of the deferred model. Putting this data together, our cost-efficiency analysis of the pre-emptive model as experienced at UCLA and represented in Figure 2 revealed a QALY of 63.8 years while the deferred model illustrated a QALY of 59.7 years after transplant. Incorporating the actual costs of UCLA's pre-emptive model and the forecast costs of the deferred model with these QALY values, the ICER of the pre-emptive model over the deferred model calculated yielded ($2,367)/QALY. Performing a sensitivity analysis by varying the probabilities according to ranges outlined in the preceding Methods section, it was illustrated that in all conditions the ICER remained <$50,000/QALY, indicating pre-emptive therapy cost-effectiveness across the outcome space. The maximum recorded ICER was $5740/QALY.
DISCUSSION
In this study, we outline a cost-efficiency analysis in which scheduled screening for CMV/EBV followed by treatment of asymptomatic viremic pediatric HSCT patients is compared to a deferred treatment model in which patients are not subject to routine viral PCR assays but are treated when CMV/EBV disease clinically manifests. As illustrated by an incremental cost-effectiveness ratio of ($2,367)/ QALY, the pre-emptive therapy model currently in use at UCLA is cost effective, as defined by the standard: ICER < $50,000/QALY. 24 Not only is it cost effective, the negative number indicates that the preemptive therapy paradigm saves dollars per patient due to lowering the likelihoods of high-cost disease states. Furthermore, sensitivity analyses in which probability and utility assumptions were varied across the spectrum of available data illustrated that this cost effectiveness was maintained regardless of reasonable Decision tree models outlining the potential treatment courses for hypothetical individuals subject either the Pre-emptive and Deferred Treatment paradigms. Probability of occurrence, patient utility and cost of that outcome space, along with assumption citations have been listed. All nodes reflect introduction of chance. * indicates data presented in this study.
As is often the case in cost-effectiveness analyses, the older a patient is at the moment of intervention, the fewer quality-adjusted life years intervention begets. However, sensitivity analysis within this model illustrates that as the age of the patient at transplant increases, the smaller the QALY difference becomes between the two screening paradigms; thereby rendering the lower cost pre-emptive screening paradigm more cost-effective. Put another way, the older a patient is at transplant the more similar their QALY outlook becomes regardless of screening cadence, thus making pre-emptive screening the more cost-effective approach as it is the fundamentally less costly approach.
Assay utilization patterns
An inherent risk in a practice of surveillance assays with no clinical instigator is the potential for assay overutilization. For example, as clinicians are acclimated to routine ordering of EBV and CMV assays on HSCT transplant patients, habitual diagnostic orderings might occur at inappropriate times and in unsuitable quantities. This is reflected in the data acquired from UCLA's assay utilization. For example, in several instances serologies were ordered in the peritransplant and post-transplant periods in our patient sample in patients in whom seroconversion had been well-documented previously in their hospital course, or who had recently received IVIG. Furthermore, in our study population, patients who were DÀ/RÀ, had CMV PCRs ordered in the peri-transplant and post-transplant period at the same rate as the D+/ RÀ and D+/R+ cohorts. Given that the EBPG Expert Group on Renal Transplant suggest D+/RÀ pts are the highest risk, perhaps the future adoption of these screening guidelines can aid in future cost containment.
Therapy utilization patterns
In addition, the pre-emptive model creates great cost not simply from increased assay utilization, but also from increased therapy in patients who would otherwise self-resolve their viremic state. As previously discussed, there was a 50% increase in CMV PCR testing in those patients who at one point were CMV PCR(+). As a result, testing CMV PCR(+) led to an average increased screening cost of $4,176 per CMV PCR(+) patient. Utilizing previously published rates of CMV disease without treatment, 10 of 32 viremic patients may not have developed clinical disease and were thereby treated unnecessarily for a viremia that would resolve without therapy. 16, 23 Therefore, a patient who is CMV PCR(+) and who is resultantly screened more frequently and treated constitutes a false-positive inherent in the pre-emptive screening paradigm. Combining the costs of increased screening and the therapy cost assumptions above, these false-positives result in $34,694 increase in non-weighted cost per CMV PCR(+) patient. Weighting this cost of a false-positive by the probability a false-positive will occur reveals that $3,425 of the $9,699 pre-emptive therapy weighted-cost (35%) comes from the existence of false-positives: treating and screening patients who are CMV(+) who would likely not have developed clinical CMV disease regardless of therapy.
Study limitations
This study makes use of Medicare reimbursements as a proxy for cost of a given assay. While this is a common approach for calculating the cost of care provision, this should more appropriately be recognized as the cost to the government of care provision, whereas cost to the hospital would be better accounted for by factoring in cost-to-charge ratios for University of California. But access to this data is limited. Furthermore, in addition to the direct cost of the assay that should be accounted for in calculating the costs associated with the current surveillance practice is the laboratory technician's opportunity costs for running each assay. However, given the negligible incremental time required in performance of the laboratory assays of scale, this was deemed to be an insignificant additional cost that would not alter the conclusions of this study. All told, the costs discussed in this publication are likely to be an underestimation of true costs to the hospital providing care.
Future directions
This study compares two paradigms for viremia screening in the HSCT population but with the same resultant treatment between both arms: a reliance on anti-virals in the case of CMV and a reduction in immunosuppression in the case of EBV. Concomitant to this study, efforts are underway to explore the medical and cost of novel therapies for CMV-related diseases and PTLD in the HSCT pediatric population. For example, EBV-specific cytotoxic T Lymphocytes for the prevention or treatment of PTLD has recently been shown to be medically efficacious, low cost, and safe. While the $6,095 upfront cost of EBV-specific T cells quoted in the cited study and the natural lowincidence of PLTD are concerning for a cost-ineffective intervention as compared to conventional preemptive screening and resultant anti-viral therapy, future studies may evaluate this as-of-yet unexplored cost-effectiveness comparison.
